Drug reference
Type 2 diabetes mellitus ▶BY MOUTH ▶Adult: 0.5–1.5 g daily in divided doses, dose to be taken with or immediately after meals, alternatively 0.5–1.5 g once daily, dose to be taken with or immediately after breakfast; maximum 2 g per day
PDF page 771
Avoid where possible in Acute porphyrias p. 1120
PDF page 771
→Appendix 1: sulfonylureas
PDF page 771
▶Rare or very rare Aplastic anaemia. blood disorder ▶Frequency not known Alcohol intolerance. appetite abnormal. erythema multiforme (usually in the first 6–8 weeks of therapy). exfoliative dermatitis (usually in the first 6–8 weeks of therapy). fever (usually in the first 6–8 weeks of therapy). headache. hypersensitivity (usually in the first 6–8 weeks of therapy). paraesthesia. tinnitus. weight increased
PDF page 771
The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.
PDF page 771
The use of sulfonylureas in breast- feeding should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.
PDF page 771
If necessary, the short-acting drug tolbutamide can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.
PDF page 771
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension Tablet ▶Tolbutamide (Non-proprietary) Tolbutamide 500 mg Tolbutamide 500mg tablets | 28 tablet P £34.88 DT = £20.66 | 112 tablet P £82.64 BLOOD GLUCOSE LOWERING DRUGS › THIAZOLIDINEDIONES
PDF page 771
0.5–1.5 g daily in divided doses, dose to be taken
First-line fragment. Read the complete Indications and Dose section above.
PDF page 771
